Androgen deprivation therapy: monitoring and managing the complications.
Because many patients who have biochemical relapse will live for many years,preventing additional morbidity in those who are treated with ADT is of the utmost importance. No standard therapy is currently available for men who have biochemical relapse, although data are beginning to show that earlierADT may result in improved survival, at least in patients who have somewhat more advanced disease or rapid PSA doubling times or velocities. Treatment with intermittent ADT may attenuate some of the morbidities, such as loss of bone mineral density. Not all patients will experience all or even many of these complications, but patients can be empowered by learning about these beforehand and under-standing what can be done to prevent, monitor, or treat the side effects. Table 2 summarizes recommendations for baseline evaluations of men prior to initiation of ADT, and Table 3 summarizes interventions for specific complications. Better markers to distinguish patients who will benefit from ADT are needed. Newer hormonal agents or supplements are being researched. In the meantime, patients and the health care team can work together to combat complications related to ADT.
Higano
Celestia
C
Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA. thigano@washington.edu
D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D019468:Disease Management; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000150:complications / Q000628:therapy*; D018570:Risk Assessment
D000726:Androgen Antagonists